20582results about "Nervous disorder" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a synthetic nicotine composition and a preparation method thereof. The nicotine buccal film agent disclosed by the invention is prepared from the following components in parts by weight: 2 to 4 parts of nicotine clathrate compound powder, 0.2 to 0.6 part of phosphatidic acid, 0.1 to 0.3 part of tannic acid, 0.1 to 0.2 part of sodium ascorbate, 0.04 to 0.06 part of tocopherol, 0.01 to 0.02 part of ethylene diamine tetraacetic acid, 2 to 4 parts of povidone and 40 to 80 parts of absolute ethyl alcohol. The synthesized nicotine composition prepared by the invention can effectively relieve the phenomenon that the faster the nicotine is released, the stronger the bitter taste is. Meanwhile, in a high-temperature and high-humidity environment, the stability of nicotine can be effectively maintained, and the oxidation half-life period of nicotine is prolonged.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention provides information comprising at least one GSK-3 activator for use in the prevention and / or treatment of aging and aging-related conditions and diseases by increasing proteasome activity.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present disclosure provides methods of treating a neurodevelopmental disorder (NDD) in a subject by administering a therapeutically effective amount of N-acetyl leucine.

This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.

The invention discloses application of 4, 5-dialkyl imidazole cationic lipid in a drug brain delivery carrier, and belongs to the field of drug delivery. The 4-site and the 5-site of imidazole are respectively modified with alkyl with not less than 10 carbon atoms to form the 4, 5-dialkyl imidazole cationic lipid. The 1, 4, 5-dialkyl imidazole cationic lipid is mixed with a therapeutic drug and other lipid auxiliary materials to prepare drug-loaded lipid nanoparticles loaded with the therapeutic drug, and the drug-loaded lipid nanoparticles can be used as a drug delivery system for brain delivery of the therapeutic drug. The 1, 4, 5-dialkyl imidazole cationic lipid has the function of dynamically regulating and controlling opening and closing of a blood brain barrier, and reversible opening of the blood brain barrier can be achieved; the formed drug carrier can pass through a blood brain barrier and well realize brain delivery of loaded therapeutic drugs, and a new strategy is provided for brain delivery of different types of drugs.

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention relates to the field of medicinal chemistry, and particularly discloses a piperidine derivative as well as a pharmaceutical composition, application and a preparation method thereof. The piperidine derivative has the following general formula. The piperidine derivative can be effectively used for treating or preventing multiple sclerosis, and shows an unexpected synergistic effect in an animal model: the piperidine derivative not only can significantly improve neurological function impairment and promote recovery, but also can deeply reduce the levels of key proinflammatory cytokines IFN-gamma and IL-17 at the same time. The invention provides a novel small molecule candidate drug with central permeability, neuroprotection and comprehensive immune regulation functions for treatment of multiple sclerosis.

The invention relates to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating cognitive impairment of Parkinson's disease and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 180-220 parts of vinegar tortoise plastron, 90-110 parts of morinda officinalis, 90-110 parts of angelica sinensis, 90-110 parts of radix curcumae, 55-65 parts of rhizoma acori graminei, 55-65 parts of polygala tenuifolia, 180-220 parts of calcined dragon bone, 180-220 parts of caulis spatholobi and 1-3 parts of borneol. When all the medicines of the traditional Chinese medicine composition are combined, the compatibility of monarch, minister, assistant and guide is performed, so that the traditional Chinese medicine composition has the effects of tonifying kidney, promoting blood circulation, dispersing blood stasis and inducing resuscitation, can relieve cognitive impairments such as space navigation, space exploration, working memory and the like of a Parkinson's disease cognitive impairment model mouse caused by chronic hypoperfusion, and realizes the treatment effect on the Parkinson's disease cognitive impairment; good application prospects are realized.

The invention discloses a scorpion anti-inflammatory polypeptide as well as a screening method and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The scorpion anti-inflammatory polypeptide is one of G4, G5 and G17. The method comprises the following steps: detecting a scorpion buthus martensii polypeptide extract through nanoElute 2 nanoliter liquid phase separation, timsTOFPro2 mass spectrometry and BPS Novor search analysis, screening a scorpion buthus martensii polypeptide, and further synthesizing the screened candidate polypeptide by adopting a solid-phase synthesis method; the effect of the synthesized candidate polypeptide on inhibiting microglial cell inflammation is evaluated through a qPCR method, and then the scorpion buthus martensii anti-inflammatory polypeptide is screened out. The Buthus martensii Karsch anti-inflammatory polypeptides G4, G5 and G17 screened by the method, especially G5, can significantly inhibit microglial cell inflammation and present concentration dependence, a theoretical basis is provided for medicinal development of Buthus martensii Karsch polypeptides, and a potential anti-neuroinflammation mechanism of the Buthus martensii Karsch polypeptides is disclosed.

The invention provides a compound of a GLP-1R agonist or modulator with a structure as shown in a formula (I).

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention provides a benzofuranone compound as well as a pharmaceutical composition and application thereof, and relates to the technical field of medicines. The benzofuranone compound is a compound as shown in a formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. The benzofuranone compound and the pharmaceutical composition and the pharmaceutical preparation prepared from the benzofuranone compound can prevent or treat organ injury diseases, and have good treatment effects in kidney injury, liver injury, lung injury, brain injury and heart injury.

The invention provides a double-target degradation molecule based on a functionalized nucleic acid connexon and application thereof, and relates to the technical field of biological medicine, the double-target degradation molecule comprises an E3 ubiquitin ligase ligand at one end, a first target protein ligand at the other end, and the functionalized nucleic acid connexon located between the E3 ubiquitin ligase ligand and the first target protein ligand; the functionalized nucleic acid linker is a nucleotide sequence capable of specifically recognizing and combining a second target protein or a coding gene thereof, so that the protein level degradation of the first target protein and the nucleic acid level or expression level inhibition of the second target protein / gene are realized in the same molecule. Functionalized nucleic acid and a PROTAC strategy are organically combined, single-molecule double-target collaborative intervention is achieved, targeting efficiency and treatment potential are improved, higher flexibility and expandability are provided in synthesis and design, and a new molecular platform and technical route are provided for multi-target accurate treatment.

The invention relates to the technical field of bioactive peptides, in particular to a novel multifunctional collagen-like tripeptide and application thereof, an amino acid sequence contains multiple combinations, X can be selected from multiple components, 3-methoxy-4-hydroxyphenylalanine and the like are added, and the novel multifunctional collagen-like tripeptide can interact with specific proteins, activate related pathways and play multiple physiological functions and is applied to multiple fields. The collagen-like tripeptide has obvious advantages, innovates component expansion functions, improves the preparation method, improves the efficiency, reduces the cost, is matched with other components in the fields of beauty, health care and medicine, enhances the efficacy, realizes targeted delivery, and brings a new opportunity to related industries.